Goldline Pharmac

Why is Goldline Pharmac falling/rising?

As of 18-Aug, Goldline Pharmaceutical Ltd's stock price is stable at 40.09, but shows signs of downward pressure due to declining investor participation and erratic trading patterns. The stock is currently trading below several moving averages, indicating a potential bearish trend.

As of 18-Aug, Goldline Pharmaceutical Ltd's stock price is currently at 40.09, with no change from the previous trading session. The stock's performance over the past week shows a decline of 1.01%, which is slightly better than the benchmark Sensex, which fell by 1.18%. Over the past month, Goldline's stock has decreased by 0.99%, again outperforming the Sensex, which declined by 1.17%.<BR><BR>Despite the stock's current price stability, there are indicators of falling investor participation, as evidenced by a significant drop in delivery volume, which fell by 84.62% compared to the 5-day average. This decline in trading activity suggests a lack of interest among investors, which could contribute to downward pressure on the stock price.<BR><BR>Additionally, while the stock is trading higher than its 20-day moving average, it is below its 5-day, 50-day, 100-day, and 200-day moving averages, indicating a potential bearish trend in the short to medium term. The overall liquidity of the stock is also noted to be adequate for trading, but the erratic trading pattern, with the stock not trading on 2 out of the last 20 days, may further discourage investor confidence.<BR><BR>In summary, the combination of declining investor participation, erratic trading, and the stock's position relative to its moving averages suggests that Goldline Pharmaceutical Ltd's stock is facing downward pressure, contributing to its current price stability at 40.09.

Which are the latest news on Goldline Pharmac?

What does Goldline Pharmac do?

Goldline Pharmaceutical Ltd is a micro-cap company focused on marketing pharmaceutical products. It was incorporated in 2004 and became public in 2013, with a market cap of INR 39 Cr and a P/E ratio of 9.00.

Overview: <BR>Goldline Pharmaceutical Ltd is engaged in the marketing of pharmaceutical products and operates within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>History: <BR>Goldline Pharmaceutical Ltd was originally incorporated on August 2, 2004, as a private limited company named Goldline Pharmaceutical Private Limited. It was later converted into a public limited company, with the name changed to Goldline Pharmaceutical Limited on September 23, 2013. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 39 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 9.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.60 <BR>Return on Equity: 28.91% <BR>Price-to-Book: 2.76 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Goldline Pharmac?

Goldline Pharmac's peers include Rajnish Wellness, Mangalam Drugs, Vista Pharma, Parmax Pharma, ANG Lifesciences, Murae Organisor, Sandu Pharma, Chandra Bhagat, Lasa Supergeneri, and Roopa Industries. Parmax Pharma has the highest 1-year return at 219.36%, while Rajnish Wellness has the lowest at -57.29%.

Peers: The peers of Goldline Pharmac are Rajnish Wellness, Mangalam Drugs, Vista Pharma., Parmax Pharma, ANG Lifesciences, Murae Organisor, Sandu Pharma., Chandra Bhagat, Lasa Supergeneri, Roopa Industries.<BR><BR>Quality Snapshot: Average management risk is observed at Rajnish Wellness and Sandu Pharma., while Below Average management risk is found at Mangalam Drugs, Vista Pharma., Parmax Pharma, ANG Lifesciences, Murae Organisor, Chandra Bhagat, Lasa Supergeneri, and Roopa Industries. Good growth is noted at Murae Organisor, while Below Average growth is seen at Rajnish Wellness, Mangalam Drugs, Vista Pharma., Parmax Pharma, ANG Lifesciences, Sandu Pharma., Chandra Bhagat, and Lasa Supergeneri, with Excellent growth at Roopa Industries. Capital Structure is rated as Good at Sandu Pharma., Below Average at Rajnish Wellness, Mangalam Drugs, Vista Pharma., Parmax Pharma, ANG Lifesciences, Murae Organisor, Chandra Bhagat, and Roopa Industries, and Average at Lasa Supergeneri.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Parmax Pharma at 219.36%, while the lowest is Rajnish Wellness at -57.29%. Goldline Pharmac's 1-year return is not available for comparison. Additionally, Murae Organisor, Rajnish Wellness, Mangalam Drugs, Vista Pharma., and Chandra Bhagat have negative six-month returns.

How big is Goldline Pharmac?

As of 10th June, Goldline Pharmaceutical Ltd has a market capitalization of 41.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 10.35 Cr and Total Assets of 26.28 Cr reported as of March 2025. There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Goldline Pharmaceutical Ltd has a market capitalization of 41.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for Net Sales or Net Profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 10.35 Cr and Total Assets valued at 26.28 Cr.